A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Trial Profile

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Tenalisib (Primary)
  • Indications T cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors Rhizen Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2017 Results published in a Rhizen Pharmaceuticals media release.
    • 05 Dec 2017 According to a Rhizen Pharmaceuticals media release, updated results from the study will be presented at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition.
    • 06 Dec 2016 Preliminary results (n=11) assessing safety and clinical activity, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top